A blood-based diagnostic test incorporating plasma Aβ42/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: findings from a multi cohort validity analysis

A blood-based diagnostic test incorporating plasma Aβ42/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: findings from a multi cohort validity analysis

Abstract Background The development of blood-based biomarker tests that are accurate and robust for Alzheimer’s disease (AD) pathology have the potential to aid clinical diagnosis and facilitate enrollment in AD drug trials. We developed a high-resolution mass spectrometry (MS)-based test that quant...

Full description

Bibliographic Details
Main Authors: Tim West, Kristopher M. Kirmess, Matthew R. Meyer, Mary S. Holubasch, Stephanie S. Knapik, Yan Hu, John H. Contois, Erin N. Jackson, Scott E. Harpstrite, Randall J. Bateman, David M. Holtzman, Philip B. Verghese, Ilana Fogelman, Joel B. Braunstein, Kevin E. Yarasheski
Format: Article
Language:English
Published: BMC 2021-05-01
Series:Molecular Neurodegeneration
Subjects:
Alzheimer’s disease
Plasma biomarkers
Neurodegeneration, mass spectrometry
Online Access:https://doi.org/10.1186/s13024-021-00451-6

Internet

https://doi.org/10.1186/s13024-021-00451-6

Similar Items